More than 15 million Americans live with autoimmune disease today, cycling through treatments that manage symptoms without ever reaching the source. ai3Bio was founded to change that.
Our Platform
Two Platforms. One Target: CD161+ T Cells
LNP/mRNA Platform
A lipid nanoparticle delivers mRNA that triggers disease-causing T cells to self-destruct — precisely, in vivo, in one step.
Antibody Platform
A targeting antibody recruits the body's own immune cells to seek out and clear those same disease-causing T cells.
Built to Move Autoimmune Care Forward
Advanced Immunology. Autoimmunity. AI.
Jonathan Chow, Ph.D.
Director of Immunology
Jonathan Chow, Ph.D.
Director of Immunology
Latest News & Insights
What's New at ai3.Bio
Introducing DCITE: The third wave of T cell engineering
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras et scelerisque odio. Donec at arcu in mi pellentesque mollis.
Introducing DCITE: The third wave of T cell engineering
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras et scelerisque odio. Donec at arcu in mi pellentesque mollis.
Introducing DCITE: The third wave of T cell engineering
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras et scelerisque odio. Donec at arcu in mi pellentesque mollis.
